HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价

袁作为; 王永红; 黄俊; 叶杨敏

doi:10.16016/j.1000-5404.201811017

您当前的位置：

首页 >

文章列表页 >

HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价

基础医学 | 更新时间：2026-01-09

- HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价
- Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections
- 第三军医大学学报 2019年41卷第7期页码：678-683
- 作者机构：
  
  1.409099 重庆，重庆市黔江中心医院：检验科
  2.409099 重庆，重庆市黔江中心医院：输血科
- 作者简介：
  
  [ 叶杨敏，E-mail：yym273323602@163.com YE Yangmin, E-mail:yym273323602@163.com
- 基金信息：
  
  重庆市科卫联合医学科研项目(2018QNXM002);重庆市黔江区科委科研项目(黔科计2018004)
- DOI：10.16016/j.1000-5404.201811017
  中图分类号： R446.11;R447;R512.91
- 收稿：2018-11-04，
  
  修回：2019-01-29，
  
  纸质出版：2019-04-15
- 稿件说明：
移动端阅览
袁作为, 王永红, 黄俊, 等. HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价[J]. 第三军医大学学报, 2019,41(7):678-683.

Zuowei YUAN, Yonghong WANG, Jun HUANG, et al. Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections[J]. Journal of Third Military Medical University, 2019, 41(7): 678-683.
袁作为, 王永红, 黄俊, 等. HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价[J]. 第三军医大学学报, 2019,41(7):678-683. DOI： 10.16016/j.1000-5404.201811017.

Zuowei YUAN, Yonghong WANG, Jun HUANG, et al. Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections[J]. Journal of Third Military Medical University, 2019, 41(7): 678-683. DOI： 10.16016/j.1000-5404.201811017.

摘要

目的

研制区分HIV-1自然感染与HIV-1疫苗诱导产生抗体的鉴别诊断试纸条，并对其诊断性能进行评价。

方法

将前期利用原核表达获取的HIV-1包膜蛋白gp41和鉴别融合肽段SK1-SK2-SK3分别包被NC膜，结合胶体金标记抗人蛋白A，研制新型HIV-1抗体鉴别诊断试纸条；采用新型试纸条检测评价HIV-1阳性血清、HIV阴性血清、HIV血清盘、HIV天坛疫苗血清及其他交叉反应血清，并与ELISA结果进行对比。

结果

成功研制了HIV-1疫苗诱导与自然感染产生抗体的鉴别诊断试纸条，SK1-SK2-SK3检测灵敏度为93.5%，检测特异性为100.0%，联合gp41后的HIV-1检出灵敏度可达100.0%；试纸条检测结果与ELISA检测结果一致(

0.05)；采用该试纸条检测天坛疫苗血清，SK1-SK2-SK3检测带均为阴性，避免了gp41条带检出的假阳性结果。

结论

该新型HIV-1抗体诊断试纸条能够有效区分HIV-1自然感染与HIV-1疫苗接种后产生的抗体，避免目前市售试剂盒的假阳性诊断。

Abstract

Objective

To develop a differential diagnostic kit for distinguishing antibodies induced by HIV-1 infection and HIV-1 vaccine and evaluate its diagnostic performance.

Methods

Nitrocellulose membrane was coated with HIV-1 envelope protein gp41 and HIV-1 recognition fusion peptide SK1-SK2-SK3 obtained using a prokaryotic expression system. The differential diagnostic test strip for HIV-1 antibodies was prepared by assembling the coated membrane with a non-woven fabric coated with protein A-coupled colloidal gold. The performance of the test strip was evaluated using samples of HIV-positive sera

HIV-negative sera

HIV serum panel

HIV Tiantan vaccine sera and other cross-reactive sera

and the test results using this strip were compared with those by ELISA.

Results

The sensitivity of SK1-SK2-SK3 coating on the novel differential diagnostic test strip for HIV-1 antibody detection was 93.5%

with a detection specificity of 100.0%. When combined with gp41 coating

the test strip showed a diagnostic sensitivity of 100.0%. The test results with the strip were consistent with those by ELISA (

0.05). For the Tiantan vaccine serum

the SK1-SK2-SK3 coating on the strip all yielded negative results without the false positive results of the gp41 coating.

Conclusion

This novel HIV-1 antibody diagnostic test strip can effectively distinguish the antibodies produced by HIV-1 infection from those generated by HIV-1 vaccination without false positive results as are common with the currently available commercial HIV test kits.

关键词

Keywords

references

VORONIN Y, ZINSZNER H, KARG C, et al. HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians[J]. Vaccine, 2015, 33(10): 1243-1249. DOI: 10.1016/j.vaccine.2014.10.040.

ACKERMAN M E, BAROUCH D H, ALTER G. Systems serology for evaluation of HIV vaccine trials[J]. Immunol Rev, 2017, 275(1): 262-270. DOI: 10.1111/imr.12503.

KHURANA S, NORRIS P J, BUSCH M P, et al. HIV-selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection[J]. J Clin Microbiol, 2010, 48(1): 281-285. DOI: 10.1128/JCM.01573-09.

KHURANA S, NEEDHAM J, PARK S, et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes[J]. J Acquir Immune Defic Syndr, 2006, 43(3): 304-312. DOI: 10.1097/01.qai.000024 2465.50947.5f.

KHURANA S, NEEDHAM J, MATHIESON B, et al. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies[J]. J Virol, 2006, 80(5): 2092-2099. DOI: 10.1128/JVI.80.5.2092-2099.2006.

袁作为, 帅光泽, 张君, 等. HIV跨膜蛋白gp41和gp36原核表达及抗原性研究[J].第三军医大学学报, 2010, 32(21): 2281-2285.

YUAN Z W, SHUAI G Z, ZHANG J, et al. Expression of HIV trans-membrane protein gp41 and pronucleus gp36 and their antigenicity[J]. JThird Mil Med Univ, 2010, 32(21): 2281-2285.

YUAN Z W, CHEN W X, ZHANG J, et al. Development of an immunoassay for differentiating human immunodeficiency virus infections: from vaccine-induced immune response in Tiantan vaccine trials in China[J]. Clin Biochem, 2012, 45(15): 1219-1224.

袁作为, 张君, 胡接力, 等. HIV自然感染与疫苗诱导产生抗体鉴别肽的原核表达及纯化[J].中国生物制品学杂志, 2011, 24(11):1254-1258, 1263. DOI:10.13200/j.cjb.2011.11.11.yuanzw.019.

YUAN Z W, ZHANG J, HU J L, et al. Prokaryotic expression and purification of HIV differential peptides for natural infection-elicited and vaccine-induced antibodies[J]. Chin J Biologicals, 2011, 24(11):1254-1258, 1263. DOI: 10.13200/j.cjb.2011.11.11.yuanzw.019.

GINN S L, AMAYA A K, ALEXANDER I E, et al. Gene therapy clinical trials worldwide to 2017: An update[J]. J Gene Med, 2018, 20(5): e3015. DOI: 10.1002/jgm.3015.

ACKERS M L, PAREKH B, EVANS T G, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients[J]. J Infect Dis, 2003, 187(6): 879-886. DOI: 10.1086/368169.

PITISUTTITHUM P, NITAYAPHAN S, THONGCHAROEN P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults[J]. J Infect Dis, 2003, 188(2): 219-227. DOI: 10.1086/376506.

ALLEN M, ISRAEL H, RYBCZYK K, et al. Trial-related discrimination in HIV vaccine clinical trials[J]. AIDS Res Hum Retroviruses, 2001, 17(8): 667-674. DOI: 10.1089/088922201750236942.

ANDRABI R, BHIMAN J N, BURTON D R. Strategies for a multi-stage neutralizing antibody-based HIV vaccine[J]. Curr Opin Immunol, 2018, 53: 143-151. DOI: 10.1016/j.coi.2018.04.025.

KONG R, XU K, ZHOU T Q, et al. Fusion peptide of HIV-1as a site of vulnerability to neutralizing antibody[J]. Science, 2016, 352(6287): 828-833. DOI: 10.1126/science.aae0474.

LIAO H X, LYNCH R, ZHOU T Q, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus[J]. Nature, 2013, 496(7446): 469-476. DOI: 10.1038/nature12053.

DAVID D, GOOSSENS D, DESGRANGES C, et al. Molecular characterization of human monoclonal antibodies specific for several HIV proteins: analysis of the VH3 family expression[J]. Immunol Lett, 1995, 47(1/2):107-112.

ACKERS M L, PAREKH B, EVANS T G, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients[J]. J Infect Dis, 2003, 187(6): 879-886. DOI: 10.1086/368169.

ZHANG Q C, LIU Z, HOU J, et al. Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system[J]. Vaccine, 2016, 34(30): 3447-3453. DOI: 10.1016/j.vaccine.2016.05.012.

ZHANG Q C, TIAN M J, FENG Y, et al. Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain[J]. PLoS ONE, 2013, 8(4): e60557. DOI: 10.1371/journal.pone.0060557.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

新型冠状病毒疫苗佐剂的研究现状与展望

登革热防治研究进展

虫媒病防控研究与卫勤保障

肠道非B细胞淋巴瘤与克罗恩病的鉴别诊断

超声造影结合定量分析技术在鉴别诊断甲状腺良恶性结节中的应用价值